JPRN-UMIN000036375已完成未知
Efficacy and safety of VRd (bortezomib, lenalidomide, dexamethasone) induction therapy, autologous hematopoietic stem cell transplantation, KRd (carfilzomib, lenalidomide, dexamethasone) consolidation and lenalidomide maintenance therapy for newly diagnosed multiple myeloma (phase II study) - VRd/ASCT/KRd/Len maintenance (TKMC MM1801)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who are allergic to drugs used by this protocol study 2) Patients with severe cardiac dysfunction 3) Patients with active and uncontrolled infections 4) Patients with HBs antigen (+) or HCV antibody (+). 5) Patients with uncontrolled malignancies 6) Pregnant women, women who could be pregnant or women who is breast feeding 7) Patients with uncontrolled gastric ulcer 8) Past history of renal transplantation 9) Past history of pulmonary embolism, cardiac infarction and/or brain infarction 10) Patients with uncontrolled diabetes 11) severe psychiatric disorders 12) Patients with other inadequate conditions determined by investigators
研究者
相似试验
进行中（未招募）
2 期
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple MyelomaMultiple MyelomaNCT05860036Institute of Hematology & Blood Diseases Hospital, China40
进行中（未招募）
2 期
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 AbnormalitiesMultiple MyelomaNCT05850286Institute of Hematology & Blood Diseases Hospital, China20
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDRewly diagnosed Waldenstrom's macroglobulinemia (WM)MedDRA version: 8.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaEUCTR2006-003563-31-NLEuropean Myeloma Network90
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDREUCTR2006-003563-31-DKEuropean Myeloma Network90
已完成
不适用
Safety and Efficacy of Bortezomib inaddtion to Adriamycin and Intermediate-Dose Dexamethasone (iPAD) in Subjects with Relapse/Refractory Multiple Myeloma with Primary Therapies ; A PhaseI/II, Multicentre, Open-Label, Single-Arm StudyRelapse/Refractory Multiple MyelomaJPRN-UMIN000001210Division of Medical Oncology, Hematology and Infectious Disease, Department of Medicine, Fukuoka University28